Silexion Therapeutics Corp
SLXNHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, Silexion Therapeutics Corp (SLXN) is listed under Biotechnology. At a $2.0M market cap, Silexion Therapeutics Corp ranks as a micro-cap company within healthcare. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Market Cap
$2.0M
Beta
-0.36
P/E (TTM)
—
P/E (Fwd)
-0.55
EPS (TTM)
$-19.89
EPS (Fwd)
$-0.64
ROE
—
ROA
—
Cash
$2.2M
Total Debt
$1.4M
Free CF
—
52W Change
-99.3%
Annual Financials
Cash vs Debt
Where SLXN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SLXN finished 95.36% below its 150-day moving average ($7.55) and 97.01% below its 200-day moving average ($11.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SLXN overbought or oversold?
At the September 3, 2026 close, SLXN's RSI(14) was 11.9, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $2.2M in cash comfortably exceeding the $1.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods.
SLXN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. No single metric tells the full story. Reviewing SLXN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.